Galenvs develops and manufactures precision magnetic nanoparticles and DNA/RNA oligonucleotides for therapeutic and diagnostic applications. It offers end‑to‑end services—from proof‑of‑concept and in‑vitro validation to pilot‑scale production—using proprietary nanomaterial and oligonucleotide synthesis technologies to create custom, client‑specific processes.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers and developers in therapeutics and diagnostics often face lengthy development cycles and limited access to high‑quality magnetic nanoparticles and custom DNA/RNA oligonucleotides, slowing product validation and scale‑up.
Solution
Galenvs provides a vertically integrated platform that designs, synthesizes, and manufactures precision magnetic nanomaterials and DNA/RNA oligonucleotides on demand. The company offers end‑to‑end services—from proof‑of‑concept and in‑vitro validation to pilot‑scale production—using proprietary synthesis technologies and data‑driven process optimization. By delivering custom, client‑specific processes, Galenvs reduces development timelines, improves reproducibility, and enables rapid translation of biotech concepts into market‑ready products.
Target Audience
Primary customers are biotech companies, pharmaceutical developers, and diagnostic manufacturers seeking custom nanomaterials or oligonucleotides, as well as research institutions requiring rapid prototyping and pilot‑scale production.
Features
- Proprietary magnetic nanoparticle synthesis with functionalization tailored for diagnostic and therapeutic applications
- Custom DNA/RNA oligonucleotide design and manufacturing, including specialized monomers for therapeutic use
- Integrated workflow covering design, development, testing, and scale‑up within a single organization
- High‑throughput universal pathogen DNA/RNA extraction kit (magnetiQ) delivering purified nucleic acids in under 20 minutes without heating or centrifugation
- Compatibility with automated liquid‑handling platforms (e.g., Kingfisher Flex, Apex) for 96‑sample processing
- Data‑driven process optimization to accelerate feedback loops and reduce time‑to‑market